Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

Kathleen Medora / aacr - Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with…

AI Summary: A phase III trial—part of the HER2CLIMB-05 study—showed that adding tucatinib to first‑line maintenance therapy with trastuzumab and pertuzumab significantly delayed disease progression in patients with HER2‑positive metastatic breast cancer, with benefits observed across key subgroups including those with brain metastases.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Sacituzumab Govitecan trial shows comparable PFS in advanced breast cancer / 5 months

Apixaban linked to lower bleeding than rivaroxaban in head‑to‑head study / 2 months

Sanofi ousts Paul Hudson as Belén Garijo named incoming CEO / 3 months

Zoliflodacin shows promise as single-dose treatment for gonorrhea / 5 months

PAXG regimen shows superior event‐free survival in early pancreatic cancer / 6 months

First-in-human trial primes immune system to accept donor livers / 6 wks

Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 7 wks